- Home
- BL vs RNA Comparison
BL vs RNA Comparison
Compare BL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BL
- RNA
- Stock Information
- Founded
- BL 2001
- RNA 2012
- Country
- BL United States
- RNA United States
- Employees
- BL N/A
- RNA N/A
- Industry
- BL Computer Software: Prepackaged Software
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- BL Technology
- RNA Health Care
- Exchange
- BL Nasdaq
- RNA Nasdaq
- Market Cap
- BL 3.1B
- RNA 3.7B
- IPO Year
- BL 2016
- RNA 2020
- Fundamental
- Price
- BL $49.13
- RNA $26.74
- Analyst Decision
- BL Buy
- RNA Strong Buy
- Analyst Count
- BL 11
- RNA 12
- Target Price
- BL $65.64
- RNA $68.25
- AVG Volume (30 Days)
- BL 651.0K
- RNA 1.4M
- Earning Date
- BL 05-06-2025
- RNA 05-08-2025
- Dividend Yield
- BL N/A
- RNA N/A
- EPS Growth
- BL 78.84
- RNA N/A
- EPS
- BL 1.45
- RNA N/A
- Revenue
- BL $653,336,000.00
- RNA $10,897,000.00
- Revenue This Year
- BL $10.66
- RNA N/A
- Revenue Next Year
- BL $9.51
- RNA $134.34
- P/E Ratio
- BL $33.31
- RNA N/A
- Revenue Growth
- BL 10.74
- RNA 13.98
- 52 Week Low
- BL $43.37
- RNA $21.56
- 52 Week High
- BL $69.09
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- BL 41.99
- RNA 36.75
- Support Level
- BL $47.82
- RNA $30.12
- Resistance Level
- BL $51.06
- RNA $33.13
- Average True Range (ATR)
- BL 1.25
- RNA 2.19
- MACD
- BL 0.28
- RNA -0.34
- Stochastic Oscillator
- BL 48.32
- RNA 1.93
About BL BlackLine Inc.
BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their financial close process including account reconciliations, variance analysis of account balances, journal entry capabilities, and certain types of data matching capabilities. The majority of the revenue of the company is earned in the United States.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.